Physician profile
Deborshi Roy
NPI 1184744336
$6,005.80
in general payments reported to CMS, 2019-2025
11 companies · $827 in 2025
The $827 reported for 2025 was more than what 77% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $204 · 2021: $626 · 2022: $2,456 · 2023: $727 · 2024: $788 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,341.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,985.40 | 2021-2024 | Sinuva, Pteye Parathyroid Detection System, Stealthstation S8 Platform |
| Stryker Corporation | $1,601.90 | 2019-2025 | Xpress Loprofile, Clarifix, Clarifix Cryotherapy Device |
| Aerin Medical INC. | $349.82 | 2022-2025 | |
| Intersect Ent, INC. | $335.30 | 2019-2020 | |
| Livanova USA, INC. | $190.66 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Astrazeneca Pharmaceuticals LP | $156.56 | 2025 | Tezspire |
| Optinose US, INC. | $144.70 | 2019-2025 | |
| Neurent Medical Limited | $126.19 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Genzyme Corporation | $64.41 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $28.21 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $22.65 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborshi Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.